Skip to main content
SpringerLink
Log in

Multiple myeloma gammopathies

Commentary on “Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma” by Giovanni Barosi and Robert Peter Gale

  • Comment
  • Published:
Leukemia Submit manuscript

The Original Article was published on 28 January 2019

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Barosi G, Gale RP. Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma. Leukemia.

  2. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1770–81.

    Article  CAS  Google Scholar 

  3. Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1782–91.

    Article  CAS  Google Scholar 

  4. Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371:895–905.

    Article  Google Scholar 

  5. Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, et al. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017;4:e431–e42.

    Article  Google Scholar 

  6. McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35:3279–89.

    Article  CAS  Google Scholar 

  7. Jackson G, Davies FE, Pawlyn C, Cairns D, Striha A, Hockaday A, et al. Lenalidomide maintenance significantly improves outcomes compared to observation irrespective of cytogenetic risk: results of the myeloma XI trial. Blood. 2017;130:436.

    Google Scholar 

  8. Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Castillo J, et al. NCCN guidelines insights: multiple myeloma, version 3.2018. J Natl Compr Canc Netw. 2018;16:11–20.

    Article  Google Scholar 

  9. Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64:380–2.

    Article  Google Scholar 

  10. Sobrero AF, Pastorino A, Sargent DJ, Bruzzi P. Raising the bar for antineoplastic agents: how to choose threshold values for superiority trials in advanced solid tumors. Clin Cancer Res. 2015;21:1036–43.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE, USA

    Sarah A. Holstein

  2. Department of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA

    Vera J. Suman

  3. Department of Medicine, Transplant and Cellular Therapy Program, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

    Philip L. McCarthy

Authors
  1. Sarah A. Holstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vera J. Suman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Philip L. McCarthy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sarah A. Holstein.

Ethics declarations

Conflict of interest

SAH reports serving as an advisory board member for Celgene, Takeda and Adaptive Biotechnologies, and as a consultant for Celgene and GlaxoSmithKline, outside the submitted work. PLM reports receiving honoraria from Bristol-Myers Squibb, Celgene, Sanofi-Aventis, Takeda and Binding Site, research funding from Celgene, and has served on advisory committees/review panels/board membership for Bristol-Myers Squibb, Celgene, Sanofi-Aventis, Takeda, Binding Site and Karyopharm outside the submitted work. VJS declares that she has no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Holstein, S.A., Suman, V.J. & McCarthy, P.L. Commentary on “Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma” by Giovanni Barosi and Robert Peter Gale. Leukemia 33, 565–566 (2019). https://doi.org/10.1038/s41375-018-0359-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-018-0359-7

  • Springer Nature Limited

This article is cited by

Search

Navigation